We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Labcorp Holdings (LH - Free Report) will report quarterly earnings of $4.79 per share in its upcoming release, pointing to a year-over-year increase of 10.1%. It is anticipated that revenues will amount to $3.72 billion, exhibiting an increase of 5.4% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Labcorp metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Biopharma Laboratory Services' will reach $806.31 million. The estimate suggests a change of +2.7% year over year.
It is projected by analysts that the 'Revenues- Diagnostics Laboratories' will reach $2.92 billion. The estimate indicates a year-over-year change of +6.1%.
Analysts predict that the 'Adjusted Operating Income- Diagnostics Laboratories' will reach $519.16 million. Compared to the current estimate, the company reported $482.80 million in the same quarter of the previous year.
The consensus estimate for 'Adjusted Operating Income- Biopharma Laboratory Services' stands at $128.04 million. Compared to the present estimate, the company reported $123.30 million in the same quarter last year.
Labcorp shares have witnessed a change of +12.2% in the past month, in contrast to the Zacks S&P 500 composite's +1.9% move. With a Zacks Rank #2 (Buy), LH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Labcorp Holdings (LH - Free Report) will report quarterly earnings of $4.79 per share in its upcoming release, pointing to a year-over-year increase of 10.1%. It is anticipated that revenues will amount to $3.72 billion, exhibiting an increase of 5.4% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Labcorp metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Biopharma Laboratory Services' will reach $806.31 million. The estimate suggests a change of +2.7% year over year.
It is projected by analysts that the 'Revenues- Diagnostics Laboratories' will reach $2.92 billion. The estimate indicates a year-over-year change of +6.1%.
Analysts predict that the 'Adjusted Operating Income- Diagnostics Laboratories' will reach $519.16 million. Compared to the current estimate, the company reported $482.80 million in the same quarter of the previous year.
The consensus estimate for 'Adjusted Operating Income- Biopharma Laboratory Services' stands at $128.04 million. Compared to the present estimate, the company reported $123.30 million in the same quarter last year.
View all Key Company Metrics for Labcorp here>>>Labcorp shares have witnessed a change of +12.2% in the past month, in contrast to the Zacks S&P 500 composite's +1.9% move. With a Zacks Rank #2 (Buy), LH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .